CAR-T immunotherapy is one of the most resource-intensive and personalized therapies in clinical trials today. It can deliver astounding results, but the scalability and affordability of the therapy have always been in question.
As a joint leader in the CAR-T immunotherapy space, Kite Pharma closed day three of the J.P. Morgan Healthcare Conference with a roadmap for commercializing its lead biologic, KTE-C19/axi-cel, to treat thousands of patients with diffused large B-cell lymphoma.
Chairman and CEO Arie Belldegrun said the company plans to finalize its BLA submission with the FDA in the first quarter of 2017.
